UK Biomedical Cluster, Pfizer Partner to Translate Basic Science into Rare Disease Treatments | GenomeWeb

NEW YORK (GenomeWeb) – The Global Medical Excellence Cluster (GMEC), a UK non-profit focused on advancing translational research, has inked an agreement with Pfizer to use molecular and genomic technologies to develop medicines for treating rare diseases.

Under the five-year initiative, investigators at GMEC's partnering universities will work with Pfizer scientists in joint programs aiming to translate basic research into new drugs for treating rare diseases, GMEC said today.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Intelligence officials in the US have added gene editing to a list of weapons of mass destruction.

In Cell this week: characterization of functional genomic features in breast cancer cell lines, epigenetic pattern linked to obesity, and more.

President Obama's proposed budget for fiscal year 2017 includes an increase for NIH, but seeks some of it as mandatory funding.

Sure Genomics begins to offer direct-to-consumer genome sequencing for $2,500.

Mar
03
Sponsored by
Agilent Technologies

This webinar will discuss the use of a hybrid capture-based FFPE DNA sequencing methodology with the potential for advancing precision oncology studies.